CN114072406B - Flna-结合化合物及其盐酸盐的固体多晶型物 - Google Patents

Flna-结合化合物及其盐酸盐的固体多晶型物 Download PDF

Info

Publication number
CN114072406B
CN114072406B CN202080030057.XA CN202080030057A CN114072406B CN 114072406 B CN114072406 B CN 114072406B CN 202080030057 A CN202080030057 A CN 202080030057A CN 114072406 B CN114072406 B CN 114072406B
Authority
CN
China
Prior art keywords
crystalline
ray powder
powder diffraction
peaks
diffraction pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080030057.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN114072406A (zh
Inventor
M·扎姆卢特
L·B·巴碧尔
S·A·库切拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kasava Science Co
Penn Therapy
Original Assignee
Kasava Science Co
Penn Therapy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kasava Science Co, Penn Therapy filed Critical Kasava Science Co
Priority to CN202510171428.0A priority Critical patent/CN120004896A/zh
Publication of CN114072406A publication Critical patent/CN114072406A/zh
Application granted granted Critical
Publication of CN114072406B publication Critical patent/CN114072406B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202080030057.XA 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物 Active CN114072406B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510171428.0A CN120004896A (zh) 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962808609P 2019-02-21 2019-02-21
US62/808609 2019-02-21
PCT/US2020/019305 WO2020172584A1 (en) 2019-02-21 2020-02-21 Solid polymorphs of a flna-binding compound and its hydrochloride salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510171428.0A Division CN120004896A (zh) 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物

Publications (2)

Publication Number Publication Date
CN114072406A CN114072406A (zh) 2022-02-18
CN114072406B true CN114072406B (zh) 2025-03-18

Family

ID=72141575

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080030057.XA Active CN114072406B (zh) 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物
CN202510171428.0A Pending CN120004896A (zh) 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510171428.0A Pending CN120004896A (zh) 2019-02-21 2020-02-21 Flna-结合化合物及其盐酸盐的固体多晶型物

Country Status (10)

Country Link
US (4) US11370791B2 (https=)
EP (1) EP3927707A4 (https=)
JP (2) JP2022523196A (https=)
KR (1) KR20210135530A (https=)
CN (2) CN114072406B (https=)
AU (1) AU2020224678B2 (https=)
BR (1) BR112021016622A2 (https=)
CA (1) CA3131146A1 (https=)
IL (1) IL285763A (https=)
WO (1) WO2020172584A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts
US20220233512A1 (en) * 2020-11-03 2022-07-28 Cassava Sciences, Inc. Inhibiting an immune response mediated by one or more of tlr2, rage, ccr5, cxcr4 and cd4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004014304A1 (de) 2004-03-22 2005-10-06 Grünenthal GmbH Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen
US8653068B2 (en) * 2009-10-30 2014-02-18 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
US9340558B2 (en) * 2007-11-02 2016-05-17 Pain Therapeutics Inc. Filamin a binding anti-inflammatory and analgesic
US8614324B2 (en) * 2008-10-31 2013-12-24 Pain Therapeutics, Inc. Filamin A binding anti-inflammatory and analgesic
WO2010051497A1 (en) * 2008-10-31 2010-05-06 Pain Therapeutics, Inc. Filamin a binding anti-inflammatory and analgesic
EP2549873A1 (en) * 2010-03-25 2013-01-30 Merck Sharp & Dohme Corp. Novel spiro imidazolones as glucagon receptor antagonists, compositions, and methods for their use
WO2014012054A1 (en) 2012-07-13 2014-01-16 Pain Therapeutics, Inc. Alzheimer's disease assay in a living patent
EP2882428B1 (en) * 2012-07-13 2019-01-16 Pain Therapeutics, Inc. A method of inhibiting tau phosphorylation
US9433604B2 (en) * 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells
WO2020172584A1 (en) 2019-02-21 2020-08-27 Pain Therapeutics, Inc. Solid polymorphs of a flna-binding compound and its hydrochloride salts

Also Published As

Publication number Publication date
JP2022523196A (ja) 2022-04-21
WO2020172584A1 (en) 2020-08-27
US12391693B2 (en) 2025-08-19
AU2020224678A1 (en) 2021-09-16
US20240400566A1 (en) 2024-12-05
JP2024054139A (ja) 2024-04-16
US20220340574A1 (en) 2022-10-27
EP3927707A4 (en) 2022-11-09
US12065440B2 (en) 2024-08-20
US11370791B2 (en) 2022-06-28
US20200270250A1 (en) 2020-08-27
CN114072406A (zh) 2022-02-18
CN120004896A (zh) 2025-05-16
AU2020224678B2 (en) 2024-03-14
NZ779310A (en) 2024-01-26
BR112021016622A2 (pt) 2021-11-03
IL285763A (en) 2021-10-31
EP3927707A1 (en) 2021-12-29
KR20210135530A (ko) 2021-11-15
CA3131146A1 (en) 2020-08-27
US20250084083A1 (en) 2025-03-13

Similar Documents

Publication Publication Date Title
US9193730B2 (en) Short-acting benzodiazepine salts and their polymorphic forms
CN101501019B (zh) 短效苯并二氮杂*盐及其多晶型
KR102618114B1 (ko) 이브루티닙과 카복실산의 공결정체
US12391693B2 (en) Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
JP6447508B2 (ja) ３−（イミダゾ［１，２−ｂ］ピリダジン−３−イルエチニル）−４−メチル−Ｎ−｛４−［（４−メチルピペラジン−１−イル）メチル］−３−（トリフルオロメチル）フェニル｝ベンズアミドおよびその一塩酸塩の結晶形
CN121652120A (zh) Btk抑制剂的晶型
KR20230038229A (ko) 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
US12209073B2 (en) Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor
TW201718516A (zh) 組蛋白去乙醯酶抑制劑之晶形
US12202834B2 (en) Solid state forms of oclacitinib maleate
JP2025528904A (ja) Ｔｙｋ２阻害剤およびその使用
JP2015534989A (ja) ｛ｓ−３−（４−アミノ−１−オキソ−イソインドリン−２−イル）（ピペリジン−３，４，４，５，５−ｄ５）−２，６−ジオン｝の固体形態
TW202415667A (zh) (S)-7-氧雜-2-氮雜-螺[4.5]癸烷-2-甲酸[7-(3,6-二氫-2H-吡喃-4-基)-4-甲氧基-噻唑并[4,5-c]吡啶-2-基]-醯胺之新穎結晶型及其共晶型
US20230105181A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2026072992A1 (en) Salts and solid forms of muscarinic receptor agonists
WO2024255833A1 (zh) 吡啶氮氧化合物与富马酸的共晶体及其组合物、用途和制备方法
WO2026067446A1 (zh) 一种大稠环化合物的盐、多晶型物及其应用
JP2022544041A (ja) ベネトクラクスの多形及び多形を調製するための方法
CN114040908A (zh) 一种凝血因子XIa抑制剂的晶型及其制备方法
HK1137739B (en) Short-acting benzodiazepine salts and their polymorphic forms

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: American Texas

Applicant after: Kasava Science Co.

Address before: American Texas

Applicant before: Penn therapy

Country or region before: U.S.A.

GR01 Patent grant
GR01 Patent grant